Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥ 3 months and \< 21 years~* Patients diagnosed with malignant hemopathies (Acute Lymphoblastic leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma (NHL)) in complete morphological remission or Myelodysplastic Syndromes (MDS), Solid Tumors or non malignant hematological disorders (SCID, Acquired and Congenital Aplastic Anemia, other Primary Immunodeficiencies, Life-threatening Cytopenia) eligible for an allogeneic transplantation and lacking a related or unrelated HLA-matched donor~* Patients displaying an HLA-partially matched family donor~* Lansky/Karnofsky score \> 40, WHO \> 4~* Signed written informed consent~Exclusion Criteria:~* Grade \>II acute GvHD or chronic extensive GvHD at the time of inclusion~* Patient receiving an immunosuppressive treatment for GvHD treatment at the time of inclusion~* Dysfunction of liver (ALT/AST \> 5 times normal value, or bilirubin \> 3 times normal value), or of renal function (creatinine clearance \< 30 ml / min)~* Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction \<40%)~* Current active infectious disease (including positive HIV serology or viral RNA)~* Serious concurrent uncontrolled medical disorder~* Pregnant or breast feeding female patient~* Lack of parents' informed consent.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- TCR alfa beta depleted graft, infusion (Type: EXPERIMENTAL): The leukapheresis product will undergo TCR alfa beta negative selection following the standardized protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).